• F Dresco, E Puzenat, M Delobeau, D Salard, T Lihoreau, F Pelletier, and F Aubin.
• Service de dermatologie, UMR Inserm 1098, CHU et université de Franche Comté, Besançon, France.
• Rev Med Interne. 2020 Mar 1; 41 (3): 152-159.

BackgroundBelimumab is currently approved for the treatment of active systemic lupus erythematosus (SLE). The aim of our study was to evaluate the efficacy of belimumab in the treatment of cutaneous lupus erythematosus (CLE), resistant to conventional therapy.Patients And MethodsSeven patients with resistant and progressive LEC and treated with belimumab were retrospectively analyzed. The efficacy and safety of belimumab were evaluated with the CLASI, RCLASI and DLQI scores, after 6 to 12 months of treatment.ResultsEighty-three percent of patients demonstrated a significant clinical improvement based on the CLASI and RCLASI activity scores, including 1 complete and 4 partial responses, without worsening of CLASI and RCLASI damage scores. Eighty percent of patients also showed an improvement of their quality of life (DLQI). Oral corticosteroids were discontinued in all patients. Tolerance was acceptable with only one serious adverse event (bacteriema).ConclusionOur study suggests the clinical efficiency of belimumab in a series of 7 patients presenting a resistant and progressive CLE.Copyright © 2019 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

26 keywords...

hide…